|
|
||||||||
CLINICAL STUDY |
Woman and Child Division, Ullevål University Hospital, 1 Department of Endocrinology, Rikshospitalet University Hospital, 2 Department of Public Health and Primary Health Care, University of Bergen, 5025 bergen, Norway and 3 Department of Obstetrics and Gynecology, Rikshospitalet University Hospital, 0027 Oslo, Norway
(Correspondence should be addressed to T Henriksen; Email: tore.henriksen{at}rikshospitalet.no)
| Abstract |
|---|
|
|
|---|
Design: Prospective population based cohort study of 2050 pregnancies and nested case control study. Methods: Outcome measures were adjusted risks for macrosomia in relation to early second trimester maternal serum lipids, glucose and insulin (cohort study) and leptin and insulin-like growth factor (73 cases and 146 matched controls).
Results: Gestational diabetes was not independently associated with fetal macrosomia. First trimester body mass index (BMI), gestational weight gain and placental weight were associated with macrosomia. High serum insulin and non-high density lipoprotein (HDL)-cholesterol and low serum HDL-cholesterol were associated with increased risk of macrosomia independent of BMI, weight gain, placental weight and gestational diabetes. Slim women with macrosomic infants had higher insulin compared with those with normal weight infants. This relation was not found among obese women. Leptin was not associated with macrosomia after adjusting for maternal BMI.
Conclusions: Blood parameters known to be associated with the metabolic syndrome were risk factors for macrosomia independent of maternal BMI.
| Introduction |
|---|
|
|
|---|
Maternal anthropometric parameters, such as pre-gestational body size indices and gestational weight gain have repeatedly been shown to be independent determinants of the size of the offspring (912). The increasing prevalence of being overweight among young women as well as the decline in smoking, is currently considered a major cause of large infants in the population (13). Overweight is, however, associated with complex changes in metabolic and endocrine parameters, changes that may differ among subgroups of obese individuals (14). Therefore, maternal metabolic and endocrine factors may well be independent determinants of fetal growth. Glucose intolerance in pregnancy, including gestational diabetes, has traditionally been considered a determinant of accelerated fetal growth independent of maternal size, although the evidence cannot be considered conclusive on a general basis (1517). With overweight there also follows changes in lipid metabolism and a variety of accompanying hormonal alterations (14). Apart from maternal plasma glucose, studies on the role of maternal metabolic parameters as independent determinants of fetal growth are limited (18, 19).
The purpose of the present study was to investigate prospectively if maternal metabolic parameters associated with maternal weight were independent determinants of large baby size at term.
| Materials and methods |
|---|
|
|
|---|
This study was part of a large prospective cohort study performed at Aker Hospital in 19951996, conducted to assess risk factors for the development of preeclampsia (20). Aker was at that time a university hospital with all levels of obstetric care. The hospital covered defined geographical areas of Oslo city, representing all socio-economic classes. Approximately 95% of the pregnant women in these areas gave birth at this hospital. The transfer of women to other hospitals because of medical reasons was exceptional (< 0.5%).
All pregnant women in the areas were offered an ultrasound investigation at 1719 weeks of gestation. In a period of 21 months in 19951996, women of Norwegian ancestry who received the offer of ultrasound screening were simultaneously asked to provide a blood sample. Women with pre-gestational diabetes were not included. Blood samples from 2434 women were obtained, i.e. from 93.4% of the recruited women. Women with multiple pregnancies (n = 28) and preterm births (before 37 completed weeks) (n = 100) were excluded from the present study. Seven women were excluded because the medical records were missing and 5 women because information on birth weight was unavailable. Two hundred and forty-four women were lost for follow-up mainly because they moved out of the area. Thus the study population consisted of 2050 pregnant women.
Maternal anthropometry and medical status (age, parity, smoking, first trimester weight, height, gestational weight gain, blood pressures) and pregnancy outcome (preeclampsia, gestational diabetes, birth weight, birth length, gestational age, gender of the baby, placental weight) were retrieved from medical records after delivery by Torun Clawsen. The diagnosis of gestational diabetes was based on an oral fasting glucose tolerance test (OGTT, serum glucose > 7.8 mmol/l 2 h after 75 g glucose). In Norway, OGTT is performed at 28 weeks of gestation in women at risk for diabetes mellitus (glucosuria, previous gestational diabetes, previous fetal macrosomia (birth weight > 4500 g), previous perinatal death, maternal overweight (body mass index (BMI) > 27 kg/m2), diabetes mellitus in close family). The diagnosis of preeclampsia was based on the presence of proteinuria and pregnancy-induced hypertension. Proteinuria was defined by two readings of
+ 1 on a dipstick (300 mg/24 h) with an interval of
6 h between the tests. Pregnancy-induced hypertension was defined either as blood pressure
140/90 mmHg or as an increase in diastolic pressure of
15 mmHg compared with average measurements before 20 weeks of gestation. In both cases two measurements taken
6 h apart were required.
We defined macrosomia as birth weight above 4500 g or a z-score above the 95 percentile (see Statistical analysis below).
Nested matched case control study among women with term pregnancies and without diabetes or preeclampsia
Seventy-three women from the study population who gave birth to a baby with a birth weight above 4500 g at term and without gestational diabetes or preeclampsia had frozen blood samples eligible for leptin and insulin-like growth factor-I (IGF-I) analyses. The controls (n = 146) were pregnant women from the study population without gestational diabetes or preeclampsia and who delivered a baby with a birth weight of 3000 to
4000 g. For each case, two controls matched for age, parity and gestational age were selected within the study population.
Blood samples
Blood samples were drawn in the non-fasting state. The blood samples were allowed to coagulate before centrifugation at 400 g for 10 min. The serum samples were transferred on ice to a (70 °C freezer within 140 min. Routine serum chemistries were performed by staff at Aker University Hospital for all women in the cohort at the time of collection, to determine serum lipids (triglycerides, total cholesterol, high density lipoprotein (HDL)-cholesterol, non-HDL-cholesterol) and glucose concentrations. Serum insulin was assayed by RIA with a kit from DPC (Los Angeles, CA, USA). The concentration of leptin was assayed with a kit from Linco Research Inc. (St Charles, MO, USA). Serum levels of IGF-I were analyzed by IRMA (Nichols Institute, Nijmegen, The Netherlands). The intra- and interassay coefficients of variation were < 11% for all assays.
The study was approved by the Regional Medical Ethics Committee and written informed consent was obtained from the participants.
Statistical analysis
For data analysis we used the statistical program 11.0 SPSS for Windows (SPSS Inc, Chicago, IL, USA).
Birth weight was dichotomized as
4500 g and > 4500 g. Since gestational age was significantly longer among infants > 4500 g than infants
4500 g, we standardized birth weights within weeks of gestational age and by gender of the offspring. Standardized birth weights were based on data from the Medical Birth Registry of Norway (21), and were calculated as z-scores by subtracting the calculated mean of the reference population from the observed value and dividing by the S.D. We defined macrosomia as the z-score above the 95 percentile. The 2-sample t-test or the non-parametric Mann-Whitney test was used to compare continuous variables between women with macrosomic and normal weight babies. Proportions were compared using the
2 test. Correlations were estimated by Pearson correlation coefficient. Relative risks were evaluated by logistic regression analyses. We used the odds ratio (OR) to approximate relative risk. In all regression analyses, covariates were represented by indicator variables to allow for non-linear doseresponse relationships. BMI was defined as kg/m2. The women were classified according to first trimester BMI as lean (
20), normal weight (20 to
25), overweight (25 to
30), and obese (> 30). For maternal age we used the categorization
25, 25 to
30, 30 to
35 and > 35 years. Maternal first trimester weight, height, weight gain, placental weight and the blood sample variables were categorized according to quartiles of their distributions. For variables with a high number of missing values (above 30) those cases were included in the analysis as a separate category. Tests for linear trends were used to assess graded associations (missing category excluded).
In the nested case control part of the study, OR for birth weight above 4500 g was evaluated by use of conditional logistic regression analysis. Stratified Cox regression models were used to fit the conditional logistic regression model, because these two models give the same likelihood function and thus the same estimates (22). Also, in these regression analyses the covariates were represented by indicator variables to allow for non-linear relationships. P < 0.05 was considered significant.
| Results |
|---|
|
|
|---|
Background characteristics are presented in Table 1
. Eighty-eight (4.3%) of the 2050 women in the cohort gave birth to a baby with a birth weight above 4500 g, whereas 104 women had a z-score for birth weight above the 95 percentile.
|
There was a positive correlation in the cohort between first trimester BMI and concentrations of insulin (r = 0.23, P < 0.001), glucose (r = 0.21, P < 0.001), triglycerides (r = 0.26, P < 0.001), total cholesterol (r = 0.08, P < 0.001) and non-HDL-cholesterol (r = 0.11, P < 0.001), and an inverse correlation between BMI and HDL-cholesterol (r = (0.21, P < 0.001). Body mass index was also correlated to placental weight (r = 0.12, P < 0.001) and to gestational weight gain (r = (0.09, P < 0.001).
Among lean women (BMI
20) insulin and glucose concentrations were higher for women who delivered macrosomic babies (birth weight above 4500 g) compared with those who had non-macrosomic infants (Table 2
). In contrast, there were no differences in insulin and glucose levels among obese women (BMI > 30) who had normal weight and high weight babies (> 4500 g). Similar results were obtained when macrosomia was defined as a z-score for birth weight above the 95 percentile (data not shown). Maternal weight gain was also higher at all BMI levels except for those women with BMI above 30. Placental weight was higher at all BMI levels for women delivering macrosomic (> 4500 g) infants compared with those with non-macrosomic infants.
|
|
There was no difference in age, gestational age and parity between cases and controls (matched parameters) (Table 4
). Maternal weight gain and placental weight were higher among cases compared with controls. The proportion of smokers was lower, whereas the proportion of male infants was higher among the cases.
|
Women with macrosomic babies had higher second trimester leptin concentrations compared with women with normal weight babies. IGF-I concentrations were similar in the two groups (Table 4
).
By conditional univariate logistic regression analyses high levels of leptin were associated with a birth weight above 4500 g. After adjusting for maternal BMI, leptin was not associated with high birth weight (data not shown).
| Discussion |
|---|
|
|
|---|
The study was considered population based even though it was performed in a hospital setting. The reason is that the obstetric care in Oslo at the time of the study was based on the principle that each hospital took care of all deliveries in defined geographical areas. The study population has been described elsewhere (20). Briefly, biases due to socio-economic selection, transfer to other hospitals or moving are unlikely. The study population included, however, only Scandinavian speaking (Caucasian) women. Validity of the anthropometric and clinical data was ascertained by a review of each medical record.
All the women in the current study were non-fasting mainly because it was impracticable to obtain fasting blood samples from all the participants. However, by testing non-fasting samples we eliminated the possibility to assess an indicator of insulin sensitivity. Thus the effect of insulin sensitivity as an independent determinant of fetal macrosomia remains to be clarified in the current context. Non-fasting blood values may, however, better reflect the normal physiological state. However, a consequence of using non-fasting samples is larger variation in the values measured due to difficulties in standardization, thereby increasing the risk of type 2 errors. It is also possible that blood values may be predictive in fasting but not in non-fasting states but also vice versa. Serum levels of triglycerides, glucose and insulin are especially sensitive to prandial status (food intake). The blood parameters analyzed in the current study were selected because they are generally closely related to BMI and the metabolic syndrome. We found that triglycerides, glucose and insulin were all closely correlated to maternal BMI indicating also that in a non-fasting state these variables reflect differences in metabolism in pregnant women according to their BMI.
Gestational diabetes has generally been considered an independent predictor of high birth weight although not all reports are consistent when adjusting for maternal BMI (1517). The discrepancies between the studies may reflect differences in the prevalence of type II diabetes in the background population and variation in screening practices, diagnostic criteria and treatment modalities. In the present study, the effect of gestational diabetes on high birth weight after adjustment for BMI did not reach statistical significance. We cannot exclude a certain effect of gestational diabetes in the present population because after adjustment the odds ratio (95% confidence interval) was 2.4 (0.87.2). However, the main message to be taken from the majority of the studies performed is, in our opinion, that on a population basis high maternal BMI is a more important determinant of large size at birth than gestational diabetes.
Serum insulin was apparently an independent predictor of high birth weight (Table 3
). However, insulin may be an effect modifier because among low BMI women insulin was higher for those delivering high birth weight babies. For those with high BMI there was no difference in the levels of insulin. Thus it may be questioned if adjustment for BMI is justifiable. To the extent that high serum insulin reflects reduced insulin sensitivity our finding indicates that slim women with insulin resistance are at increased risk of having a baby of large size. Interestingly, none of these women had gestational diabetes. On a population basis, slim women with high serum insulin do not, however, contribute markedly to the prevalence of macrosomic newborns. Our finding does, however, show that maternal insulin levels may, under given metabolic conditions, be independently involved in fetal growth.
In the current study, the serum glucose level was only a borderline, independent, risk factor of having a macrosomic infant. The relation between glucose and maternal BMI in relation to the size of the baby showed a similar trend as for insulin. This finding supports our notion (see above) that slim women with large babies may have decreased insulin sensitivity.
A high triglyceride level was not an independent risk factor for macrosomia in our study. We are not aware of previous studies where maternal serum insulin and triglyceride levels before 20 weeks of gestation have been related to birth weight. Later in pregnancy (2428 weeks of gestation), however, triglyceride levels have been found to be independently correlated to birth weight, even after adjustment for maternal BMI (18). Similarly, obese women with macrosomic infants had higher serum triglyceride levels late in pregnancy than those without macrosomia (27). Thus, maternal triglyceride levels may be a significant determinant of fetal size in late but not in early pregnancy.
Serum leptin was, as expected, related to maternal BMI but not to the size of the baby after adjustment for BMI. This finding is in accordance with previous reports (28). This does not exclude the possibility that leptin may be an important mediator of the obesity-induced fetal macrosomia. Maternal serum levels of IGF-I have previously been shown not to be directly related to birth weight (29). IGF-I was, however, included in the present study because it is related to maternal weight and because we specifically wanted to study the risk of delivering a baby with weight in the upper percentiles (28). Not even with the design of the current study did we find any relation between maternal IGF-I in the first half of pregnancy and the risk of a large sized infant.
Schaefer-Graf et al. reported that pre-pregnancy obesity (BMI > 30) and a previous history of macrosomia were the only early predictors of large-for-gestational age infants among women with impaired glucose tolerance in pregnancy (30). From gestational week 28 fasting glucose level was also an independent predictor. In accordance with the results of the present study, the authors put forward the notion that different risk factors for macrosomia are predominant at different gestational ages. In particular, constitutional factors as reflected by a high BMI seem to be early determinants of large babies, whereas more specific metabolic parameters such as glucose and triglyceride levels become more important in the last trimester.
Placental weight was correlated both to maternal BMI and to infant size in our study. This finding may indicate that part of the effect of the altered physiology underlying high maternal weight may be mediated by an effect on placental nutritional capacity.
Interestingly, triglycerides and non-HDL-cholesterol were correlated to placental weight. It is therefore possible that the metabolic changes associated with maternal overweight may promote placental growth.
The mechanisms underlying the strong association between maternal BMI and other anthropometric parameters and birth weight of the offspring remain elusive. A better insight into these mechanisms is needed especially given the increasing rate of newborns of large size in many countries (12). The short term (perinatal and obstetrical) risks of overweight mothers and fetuses are well documented (11, 24, 31). More obscure are the long term effects on the health of the next generation. There is, however, increasing evidence that fetal over-nutrition (like under-nutrition) may have adverse effects on health of the next generation (32) This is clearly illustrated by the data indicating that exposure to a diabetic state in utero, apparently independent of genetic factors, increases the risk of obesity and diabetes in the next generation (33, 34). As pointed out by Catalano, a vicious cycle may be established with profound consequences for the health of future generations (7). This perspective is strengthened by the growing insight into the role of nutritional factors in epigenetic regulation of genes during fetal development (35).
In conclusion, the present prospective study of a normal population of 2050 term deliveries showed that blood parameters generally related to maternal overweight and metabolic syndrome were independently associated with the risk of having large sized newborns, even when adjustment was made for maternal body mass index. High maternal insulin levels among slim but not overweight women were predictive of macrosomic infants. The current evidence indicates that the biological mechanisms causing the relationship between maternal overweight and large sized infants involve a complex interaction between hormonal, placental and metabolic factors that may act differently at different stages of pregnancy.
| Acknowledgements |
|---|
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
E Koch, M Bogado, F Araya, T Romero, C Diaz, L Manriquez, M Paredes, C Roman, A Taylor, and A Kirschbaum Impact of parity on anthropometric measures of obesity controlling by multiple confounders: a cross-sectional study in Chilean women J. Epidemiol. Community Health, May 1, 2008; 62(5): 461 - 470. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. R. Romundstad, G. D. Smith, T. I. L. Nilsen, and L. J. Vatten Associations of Prepregnancy Cardiovascular Risk Factors with the Offspring's Birth Weight Am. J. Epidemiol., December 15, 2007; 166(12): 1359 - 1364. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Edison, K. Berg, A. Remaley, R. Kelley, C. Rotimi, R. E. Stevenson, and M. Muenke Adverse Birth Outcome Among Mothers With Low Serum Cholesterol Pediatrics, October 1, 2007; 120(4): 723 - 733. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Johannsson, T. Henriksen, and P. O. Iversen Increase in matrix metalloproteinases from endothelial cells exposed to umbilical cord plasma from high birth weight newborns Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2007; 292(4): R1563 - R1568. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |